Last reviewed · How we verify
α-lipoic acid
α-lipoic acid acts as a cofactor for mitochondrial enzyme complexes and functions as a potent antioxidant that scavenges free radicals and regenerates other antioxidants.
α-lipoic acid acts as a cofactor for mitochondrial enzyme complexes and functions as a potent antioxidant that scavenges free radicals and regenerates other antioxidants. Used for Diabetic peripheral neuropathy, Diabetic retinopathy, Age-related cognitive decline.
At a glance
| Generic name | α-lipoic acid |
|---|---|
| Also known as | Neuropaid OD Tablet |
| Sponsor | The Catholic University of Korea |
| Drug class | Antioxidant; mitochondrial cofactor |
| Modality | Small molecule |
| Therapeutic area | Metabolic/Endocrine; Neurology; Antioxidant therapy |
| Phase | FDA-approved |
Mechanism of action
α-lipoic acid (also known as lipoic acid or thioctic acid) is an endogenous cofactor essential for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes in mitochondrial energy metabolism. Beyond its metabolic role, it exhibits antioxidant properties by directly neutralizing reactive oxygen species and indirectly enhancing cellular antioxidant defenses through regeneration of vitamins C and E and glutathione.
Approved indications
- Diabetic peripheral neuropathy
- Diabetic retinopathy
- Age-related cognitive decline
- Metabolic syndrome
Common side effects
- Nausea
- Abdominal discomfort
- Rash or pruritus
- Headache
Key clinical trials
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC (PHASE1)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- Alpha Lipoic Acid Plus Coenzyme Q10 Versus Coenzyme Q10 Alone in Asthenozoospermia (NA)
- Effect of Low-Dose Versus High-Dose Alpha-Lipoic Acid on Oxidative Stress, Inflammation, and Clinical Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (PHASE3)
- Alpha Lipoic Acid in Pediatrics on Hemodialysis (PHASE3)
- Hunger Perception and Weight-Related Outcomes Following Use of a Leptin-Supporting Dietary Supplement (NA)
- Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |